Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

People with spinal muscle atrophy (SMA), an inherited neuromuscular disease, usually experience muscle weakness that impacts movement. New research suggests that electrical spinal cord stimulation ...

New research suggests that electrical spinal cord stimulation could improve muscle function for these patients, even restoring the capability to walk. In studies at the University of Pittsburgh School ...

Nevro, with its HFXTM spinal cord stimulation device, should gain from Globus' operational scope and worldwide infrastructure. While Nevro recorded income of around $408 million, Globus Medical's ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Daily electrical stimulation of certain nerves in the spinal cord appeared to help three people with spinal muscular atrophy (SMA), an inherited disorder that causes muscles to waste away.

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

Founded in 2006, Nevro has developed the patented HFX spinal cord stimulation platform for treating chronic pain of the trunk and limb as well as diabetic neuropathy. The company also provides ...

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company entered into a definitive agreement for Globus ...